Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02274584
Other study ID # 30273-4SCAR
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received October 22, 2014
Last updated October 22, 2014
Start date March 2014
Est. completion date October 2017

Study information

Verified date October 2014
Source Peking University
Contact Jun Zhu, MD
Phone +861088196596
Email zj@bjcancer.org
Is FDA regulated No
Health authority China: Ethics Committee
Study type Interventional

Clinical Trial Summary

Currently, a majority of lymphomas cannot be cured by standard chemo-radiotherapy. Cluster of differentiation antigen 30 (CD30) is expressed in many lymphoma subtypes, such as Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). CD30 represents a very attractive target for chimeric antigen receptor (CAR)-based immune cell therapy. This study will evaluate a novel 4th generation CD30 CAR engineered with a self-withdrawal mechanism (FKBP-iCasp9) for both efficacy and safety evaluation in lymphoma patients.


Description:

A large number of lymphoma patients exhaust current treatment options and die from the disease. Innovative therapy is urgently needed. Chimeric antigen receptor (CAR)-modified T cells have demonstrated unprecedented successes in treating even late stage cluster of differentiation antigen 19 (CD19) positive B cell malignancies. Besides CD19 lymphomas, many lymphomas are CD30 positive and therefore, CD30-CAR T cells may prove to be effective in treating such patients. We have developed several generations of CD30 CARs. Preclinical studies have demonstrated effective killing of CD30 target cells. In this study, two versions of CD30 CARs, both of which are 4th generation CARs with a self-withdrawal mechanism (FKBP-iCasp9), will be evaluated in CD30 lymphoma patients. The primary goal is safety assessment including cytokine storm response and any other adverse effects. In addition, tumor targeting and disease status after treatment will also be evaluated.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date October 2017
Est. primary completion date October 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Relapsed or refractory CD30(+) lymphoma patients proved by immuno-histochemistry (IHC) or Flow-cytometry.

- Not eligible for autologous stem-cell transplantation (ASCT) or relapsed after ASCT.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

- Age=18.

- Pulse oximetry of > 90% on room air.

- Adequate hepatic function, defined as alanine transaminase (ALT) <3 x upper limit of normal (ULN), aspartate aminotransferase (AST) <3 x ULN; serum bilirubin and alkaline phosphatase <2 x ULN.

- Adequate renal function, defined as serum creatinine <2.0mg/dl.

- Adequate heart function with LVEF=50%

- Hb=80g/L

- Measurable disease can be identified.

- Life expectancy =3 months.

- Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 1 year after the study is concluded. The male partner should use a condom.

- Patients must sign an informed consent.

Exclusion Criteria:

- Uncontrolled active infection.

- Active infection with hepatitis B virus (HBV), hepatitis C virus (HCV).

- HIV positive

- Pregnant or lactating.

- Currently enrolled in another clinical trial.

- Concurrent use of systemic steroids.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Genetic:
Anti-CD30 CAR T cells
Autologous 4th generation withdrawal lentiviral-transduced anti-CD30 CAR T cells

Locations

Country Name City State
China Peking University Cancer Hospital Beijing Beijing
United States University of Florida Gainesville Florida

Sponsors (2)

Lead Sponsor Collaborator
Peking University University of Florida

Countries where clinical trial is conducted

United States,  China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients with adverse events. Determine the toxicity profile of the 4th generation CAR T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0. 2 years. Yes
Secondary Survival time of Anti-CD30 CAR T cells in vivo. Measure the survival of 4th generation CAR T cells transduced with the anti-CD30 lentiviral vector. 2 years. No
Secondary Response rates to the 4th generation CAR T cells. Describe the response rates of patients treated with 4th generation CAR T cells, including partial remission (PR), complete remission (CR), stable disease (SD) and progressive disease (PD). 2 years. No
Secondary Survival time of the patients. Evaluate the survival time of the patients treated with the 4th generation CAR T cells, including progression free survival (PFS) and overall survival (OS). 2 years. No
See also
  Status Clinical Trial Phase
Completed NCT01359982 - Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects Phase 1
Completed NCT02140736 - Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology
Completed NCT00947739 - Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma Phase 1
Completed NCT00725634 - A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma Phase 1
Completed NCT00222443 - Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy Phase 1
Recruiting NCT02211755 - Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors Phase 1
Completed NCT02048488 - A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas Phase 1/Phase 2
Recruiting NCT06148220 - A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors N/A
Completed NCT01031641 - Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing
Withdrawn NCT02786485 - Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT Phase 1
Completed NCT01387841 - Effect of Yoga in Reducing Chemotherapy Induced Nausea and Vomiting Phase 2
Completed NCT00396864 - Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma Phase 1
Terminated NCT00023166 - Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas Phase 1
Recruiting NCT04417803 - Interest of Individual Biomarkers From the Identification of Tumor Genotype by High-throughput Molecular Techniques N/A
Recruiting NCT05775406 - Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors Phase 1
Recruiting NCT01836822 - Bronchoscopic Sampling Techniques in Sarcoidosis N/A
Completed NCT02902237 - tTF-NGR Phase I Study Phase 1
Completed NCT02578316 - A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies. Phase 1
Recruiting NCT00900198 - Collection of Tissue Samples for Cancer Research
Completed NCT02740270 - Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas Phase 1